Literature DB >> 21779426

Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme.

Greg Foltz1, Jae-Geun Yoon, Hwahyung Lee, Li Ma, Qiang Tian, Leroy Hood, Anup Madan.   

Abstract

Epigenetic inactivation of tumor suppressor genes is common in human cancer. Using a large-scale whole-genome approach in an earlier study, the authors identified epigenetically silenced genes with potential tumor suppressor function in glioblastoma (GBM). Three genes identified in this analysis-DKK1, SFRP1, and WIF1-are potent inhibitors of the Wnt signal transduction pathway. Here, the authors confirm decreased expression of these genes in GBM tumor tissue samples relative to nontumor brain tissue samples using real-time PCR. They then show that expression of all 3 genes is restored in T98 GBM cells by treatment with the histone deacetylase inhibitor Trichostatin A (TSA), but only DKK1 expression is restored by treatment with the demethylating agent 5-azacytidine. Bisulfite sequencing did not reveal significant methylation in the promoter region of DKK1, whereas histone acetylation and chromatin accessibility increased significantly for all 3 genes after TSA treatment. Ectopic expression of DKK1 significantly reduces colony formation and increases chemotherapy-induced apoptosis in T98 cells. Ectopic expression of the canonical Wnt pathway inhibitors WIF1 and SFRP1 shows a relative lack of response. Chronic Wnt3a stimulation only partially reverses growth suppression after DKK1 reexpression, whereas a specific inhibitor of the JNK pathway significantly reverses the effect of DKK1 reexpression on colony formation and apoptosis in T98 cells. These results support a potential growth-suppressive function for epigenetically silenced DKK1 in GBM and suggest that DKK1 restoration could modulate Wnt signaling through both canonical and noncanonical pathways.

Entities:  

Keywords:  epigenetics; glioblastoma; histone modifications; methylation

Year:  2010        PMID: 21779426      PMCID: PMC3092177          DOI: 10.1177/1947601909356103

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  52 in total

1.  A simple method for the rapid generation of recombinant adenovirus vectors.

Authors:  R D Anderson; R E Haskell; H Xia; B J Roessler; B L Davidson
Journal:  Gene Ther       Date:  2000-06       Impact factor: 5.250

2.  Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB.

Authors:  Wen-Jing Shen; Dong-Qiu Dai; Yue Teng; Hong-Bo Liu
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

3.  Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53.

Authors:  J Wang; J Shou; X Chen
Journal:  Oncogene       Date:  2000-03-30       Impact factor: 9.867

4.  Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells.

Authors:  W Roth; C Wild-Bode; M Platten; C Grimmel; H S Melkonyan; J Dichgans; M Weller
Journal:  Oncogene       Date:  2000-08-31       Impact factor: 9.867

5.  Wnt signaling induces GLT-1 expression in rat C6 glioma cells.

Authors:  T P Palos; S Zheng; B D Howard
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

6.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

Authors:  X Yang; D L Phillips; A T Ferguson; W G Nelson; J G Herman; N E Davidson
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

7.  Menin promotes the Wnt signaling pathway in pancreatic endocrine cells.

Authors:  Gao Chen; Jingbo A; Min Wang; Steven Farley; Lung-Yi Lee; Lung-Ching Lee; Mark P Sawicki
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

Review 8.  Chromatin-remodelling mechanisms in cancer.

Authors:  Laura Lafon-Hughes; María Vittoria Di Tomaso; Leticia Méndez-Acuña; Wilner Martínez-López
Journal:  Mutat Res       Date:  2008-02-17       Impact factor: 2.433

9.  Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines.

Authors:  Jaehyouk Lee; Young Soo Yoon; Jae Hoon Chung
Journal:  Gynecol Oncol       Date:  2008-04-02       Impact factor: 5.482

10.  Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer.

Authors:  H Suzuki; M Toyota; H Carraway; H Caraway; E Gabrielson; T Ohmura; T Fujikane; N Nishikawa; Y Sogabe; M Nojima; T Sonoda; M Mori; K Hirata; K Imai; Y Shinomura; S B Baylin; T Tokino
Journal:  Br J Cancer       Date:  2008-02-19       Impact factor: 7.640

View more
  20 in total

1.  The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer.

Authors:  Luydmila A Mostovich; Tatiana Y Prudnikova; Aleksandr G Kondratov; Natalya V Gubanova; Olga A Kharchenko; Olesya S Kutsenko; Pavel V Vavilov; Klas Haraldson; Vladimir I Kashuba; Ingemar Ernberg; Eugene R Zabarovsky; Elvira V Grigorieva
Journal:  Epigenetics       Date:  2012-07-18       Impact factor: 4.528

Review 2.  Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.

Authors:  Indranil Paul; Seemana Bhattacharya; Anirban Chatterjee; Mrinal K Ghosh
Journal:  Genes Cancer       Date:  2013-11

3.  Propofol inhibits Wnt signaling and exerts anticancer activity in glioma cells.

Authors:  Wei Xu; Jiwei Zheng; Shijie Bie; Liuyu Kang; Qingjun Mao; Weiwei Liu; Jinxin Guo; Juan Lu; Rui Xia
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

4.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

Review 5.  WNT signaling in glioblastoma and therapeutic opportunities.

Authors:  Yeri Lee; Jin-Ku Lee; Sun Hee Ahn; Jeongwu Lee; Do-Hyun Nam
Journal:  Lab Invest       Date:  2015-12-07       Impact factor: 5.662

Review 6.  Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.

Authors:  Pavel Bezecny
Journal:  Med Oncol       Date:  2014-05-18       Impact factor: 3.064

7.  PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation.

Authors:  Oana Mihaela Tudoran; Olga Soritau; Loredana Balacescu; Laura Pop; Guillaume Meurice; Simona Visan; Staffan Lindberg; Alexandru Eniu; Ulo Langel; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  J Cell Mol Med       Date:  2014-10-14       Impact factor: 5.310

8.  HOTAIR is a therapeutic target in glioblastoma.

Authors:  Xuan Zhou; Yu Ren; Jing Zhang; Chuanbao Zhang; Kailiang Zhang; Lei Han; Lingping Kong; Jianwei Wei; Luyue Chen; Jingxuan Yang; Qixue Wang; Jianning Zhang; Yuqi Yang; Tao Jiang; Min Li; Chunsheng Kang
Journal:  Oncotarget       Date:  2015-04-10

9.  Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas.

Authors:  Chun-I Sze; Wan-Pei Su; Ming-Fu Chiang; Chen-Yu Lu; Yu-An Chen; Nan-Shan Chang
Journal:  Front Oncol       Date:  2013-03-19       Impact factor: 6.244

10.  Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.

Authors:  Aleksandra Majchrzak-Celińska; Marta Słocińska; Anna-Maria Barciszewska; Stanisław Nowak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2015-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.